Zhejiang Shouxiangu Pharmaceutical Co., Ltd. (SHA:603896)

SHA:603896 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	628.9	677.92	770.34	817.67	759.99	629.84
Other Revenue	13.76	13.76	14.01	11.4	7.15	6.21
Revenue	642.66	691.68	784.35	829.07	767.14	636.05
Revenue Growth (YoY)	-10.85%	-11.81%	-5.39%	8.07%	20.61%	16.33%
Cost of Revenue	125.57	133.35	135.53	129.21	126.37	105.67
Gross Profit	517.09	558.34	648.82	699.86	640.76	530.38
Selling, General & Admin	366.18	390.75	403.79	405.17	397.19	336.38
Research & Development	58.69	48.41	49.68	47.82	50.82	48.49
Other Operating Expenses	10.59	-2.21	-4.52	6.84	7.67	5.34
Operating Expenses	434.63	436.85	447.73	461.41	456.47	390.67
Operating Income	82.46	121.49	201.09	238.45	184.3	139.71
Interest Expense	-20.04	-14.78	-24.7	-13.03	-10.17	-11.72
Interest & Investment Income	20.24	36.84	51.77	29.99	31	20.29
Other Non Operating Income (Expenses)	-0.79	-0.47	-0.43	-0.68	-0.56	-0.5
EBT Excluding Unusual Items	81.86	143.08	227.72	254.73	204.57	147.79
Gain (Loss) on Sale of Investments	8.14	4.63	0.27	-1.26	-12.33	-4.91
Gain (Loss) on Sale of Assets	0.43	8.81	0.17	0.07	0.03	-
Asset Writedown	-0.02	-0.02	-0.03	-0.06	-0	-0
Other Unusual Items	46.03	18.22	26.77	24.48	8.79	10.83
Pretax Income	136.43	174.73	254.91	277.97	201.06	153.7
Income Tax Expense	0.12	0.01	0.43	0.45	0.75	1.99
Earnings From Continuing Operations	136.31	174.71	254.48	277.51	200.31	151.71
Minority Interest in Earnings	-0	-	-	0.27	0.52	-
Net Income	136.31	174.71	254.48	277.78	200.83	151.71
Net Income to Common	136.31	174.71	254.48	277.78	200.83	151.71
Net Income Growth	-40.70%	-31.34%	-8.39%	38.32%	32.37%	22.45%
Shares Outstanding (Basic)	197	199	196	194	191	184
Shares Outstanding (Diluted)	197	199	196	194	191	184
Shares Change (YoY)	0.03%	1.42%	0.77%	1.56%	3.77%	0.70%
EPS (Basic)	0.69	0.88	1.30	1.43	1.05	0.82
EPS (Diluted)	0.69	0.88	1.30	1.43	1.05	0.82
EPS Growth	-40.72%	-32.31%	-9.09%	36.19%	27.57%	21.60%
Free Cash Flow	-36.48	-293.62	-99.48	158.68	135.07	191.38
Free Cash Flow Per Share	-0.18	-1.48	-0.51	0.82	0.71	1.04
Dividend Per Share	0.270	0.270	0.390	0.440	0.311	0.240
Dividend Growth	-30.77%	-30.77%	-11.36%	41.25%	29.79%	-9.57%
Gross Margin	80.46%	80.72%	82.72%	84.41%	83.53%	83.39%
Operating Margin	12.83%	17.56%	25.64%	28.76%	24.02%	21.96%
Profit Margin	21.21%	25.26%	32.45%	33.51%	26.18%	23.85%
Free Cash Flow Margin	-5.68%	-42.45%	-12.68%	19.14%	17.61%	30.09%
EBITDA	145.38	185.96	267.62	295.78	233.47	183.05
EBITDA Margin	22.62%	26.88%	34.12%	35.68%	30.43%	28.78%
D&A For EBITDA	62.93	64.47	66.53	57.33	49.17	43.34
EBIT	82.46	121.49	201.09	238.45	184.3	139.71
EBIT Margin	12.83%	17.56%	25.64%	28.76%	24.02%	21.96%
Effective Tax Rate	0.09%	0.01%	0.17%	0.16%	0.37%	1.29%
Revenue as Reported	642.66	691.68	784.35	829.07	767.14	636.05
Advertising Expenses	-	190.46	201.21	201.3	198.54	170.35

Source: S&P Global Market Intelligence. Standard template. Financial Sources.